These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 16723546)

  • 1. In vitro and in vivo activities of rifampin, streptomycin, amikacin, moxifloxacin, R207910, linezolid, and PA-824 against Mycobacterium ulcerans.
    Ji B; Lefrançois S; Robert J; Chauffour A; Truffot C; Jarlier V
    Antimicrob Agents Chemother; 2006 Jun; 50(6):1921-6. PubMed ID: 16723546
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bactericidal activity of rifampin-amikacin against Mycobacterium ulcerans in mice.
    Dega H; Bentoucha A; Robert J; Jarlier V; Grosset J
    Antimicrob Agents Chemother; 2002 Oct; 46(10):3193-6. PubMed ID: 12234844
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activities of new macrolides and fluoroquinolones against Mycobacterium ulcerans infection in mice.
    Bentoucha A; Robert J; Dega H; Lounis N; Jarlier V; Grosset J
    Antimicrob Agents Chemother; 2001 Nov; 45(11):3109-12. PubMed ID: 11600364
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bactericidal and sterilizing activities of several orally administered combined regimens against Mycobacterium ulcerans in mice.
    Ji B; Chauffour A; Robert J; Jarlier V
    Antimicrob Agents Chemother; 2008 Jun; 52(6):1912-6. PubMed ID: 18391038
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oxazolidinones Can Replace Clarithromycin in Combination with Rifampin in a Mouse Model of Buruli Ulcer.
    Almeida DV; Omansen TF; Li SY; Lee J; Grosset JH; Converse PJ; Nuermberger EL
    Antimicrob Agents Chemother; 2019 Mar; 63(3):. PubMed ID: 30559131
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Orally administered combined regimens for treatment of Mycobacterium ulcerans infection in mice.
    Ji B; Chauffour A; Robert J; Lefrançois S; Jarlier V
    Antimicrob Agents Chemother; 2007 Oct; 51(10):3737-9. PubMed ID: 17664316
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Susceptibility of Mycobacterium ulcerans to a combination of amikacin/rifampicin.
    Marsollier L; Prévot G; Honoré N; Legras P; Manceau AL; Payan C; Kouakou H; Carbonnelle B
    Int J Antimicrob Agents; 2003 Dec; 22(6):562-6. PubMed ID: 14659652
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Curing Mycobacterium ulcerans infection in mice with a combination of rifampin-streptomycin or rifampin-amikacin.
    Lefrançois S; Robert J; Chauffour A; Ji B; Jarlier V
    Antimicrob Agents Chemother; 2007 Feb; 51(2):645-50. PubMed ID: 17101676
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemotherapy-associated changes of histopathological features of Mycobacterium ulcerans lesions in a Buruli ulcer mouse model.
    Ruf MT; Schütte D; Chauffour A; Jarlier V; Ji B; Pluschke G
    Antimicrob Agents Chemother; 2012 Feb; 56(2):687-96. PubMed ID: 22143518
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bactericidal activities of R207910 and other newer antimicrobial agents against Mycobacterium leprae in mice.
    Ji B; Chauffour A; Andries K; Jarlier V
    Antimicrob Agents Chemother; 2006 Apr; 50(4):1558-60. PubMed ID: 16569884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bactericidal activity does not predict sterilizing activity: the case of rifapentine in the murine model of Mycobacterium ulcerans disease.
    Almeida DV; Converse PJ; Li SY; Tyagi S; Nuermberger EL; Grosset JH
    PLoS Negl Trop Dis; 2013; 7(2):e2085. PubMed ID: 23469308
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Shortening Buruli Ulcer Treatment with Combination Therapy Targeting the Respiratory Chain and Exploiting Mycobacterium ulcerans Gene Decay.
    Converse PJ; Almeida DV; Tyagi S; Xu J; Nuermberger EL
    Antimicrob Agents Chemother; 2019 Jul; 63(7):. PubMed ID: 31036687
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combinations of R207910 with drugs used to treat multidrug-resistant tuberculosis have the potential to shorten treatment duration.
    Lounis N; Veziris N; Chauffour A; Truffot-Pernot C; Andries K; Jarlier V
    Antimicrob Agents Chemother; 2006 Nov; 50(11):3543-7. PubMed ID: 16954317
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of the combination rifampin-streptomycin in preventing growth of Mycobacterium ulcerans in early lesions of Buruli ulcer in humans.
    Etuaful S; Carbonnelle B; Grosset J; Lucas S; Horsfield C; Phillips R; Evans M; Ofori-Adjei D; Klustse E; Owusu-Boateng J; Amedofu GK; Awuah P; Ampadu E; Amofah G; Asiedu K; Wansbrough-Jones M
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3182-6. PubMed ID: 16048922
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of Rifampin Plus Clofazimine in a Murine Model of Mycobacterium ulcerans Disease.
    Converse PJ; Tyagi S; Xing Y; Li SY; Kishi Y; Adamson J; Nuermberger EL; Grosset JH
    PLoS Negl Trop Dis; 2015; 9(6):e0003823. PubMed ID: 26042792
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sterilizing Activity of Fully Oral Intermittent Regimens against Mycobacterium Ulcerans Infection in Mice.
    Chauffour A; Robert J; Veziris N; Aubry A; Jarlier V
    PLoS Negl Trop Dis; 2016 Oct; 10(10):e0005066. PubMed ID: 27755552
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activities of rifampin, Rifapentine and clarithromycin alone and in combination against mycobacterium ulcerans disease in mice.
    Almeida D; Converse PJ; Ahmad Z; Dooley KE; Nuermberger EL; Grosset JH
    PLoS Negl Trop Dis; 2011 Jan; 5(1):e933. PubMed ID: 21245920
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergistic activity of R207910 combined with pyrazinamide against murine tuberculosis.
    Ibrahim M; Andries K; Lounis N; Chauffour A; Truffot-Pernot C; Jarlier V; Veziris N
    Antimicrob Agents Chemother; 2007 Mar; 51(3):1011-5. PubMed ID: 17178794
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impacts of dosing frequency of the combination rifampin-streptomycin on its bactericidal and sterilizing activities against Mycobacterium ulcerans in mice.
    Ji B; Chauffour A; Aubry A; Robert J; Ibrahim M; Jarlier V
    Antimicrob Agents Chemother; 2009 Jul; 53(7):2955-9. PubMed ID: 19364857
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro activity between linezolid and other antimicrobial agents against Mycobacterium abscessus complex.
    Zhang Z; Lu J; Song Y; Pang Y
    Diagn Microbiol Infect Dis; 2018 Jan; 90(1):31-34. PubMed ID: 29089153
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.